Oculis (NASDAQ:OCS) Reaches New 52-Week High – Here’s Why

Oculis Holding AG (NASDAQ:OCS)’s stock price hit a new 52-week high during trading on Monday . The company traded as high as $18.10 and last traded at $17.57, with a volume of 58391 shares trading hands. The stock had previously closed at $17.56.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on OCS. Chardan Capital reiterated a “buy” rating and set a $28.00 target price on shares of Oculis in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Oculis in a research note on Monday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $28.80.

Oculis Stock Performance

The stock’s 50-day moving average is $16.35 and its 200 day moving average is $13.84. The stock has a market cap of $737.98 million, a price-to-earnings ratio of -9.44 and a beta of -0.33. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.